User login
ONLINE EXCLUSIVE: Audio interview with Janet Corrigan, PhD, MBA
Dr. Corrigan notes there are abundant examples of guideline adherence boosting quality outcomes, length of stay, and time to clinical stability.
Click here to listen to the audio file
Dr. Corrigan notes there are abundant examples of guideline adherence boosting quality outcomes, length of stay, and time to clinical stability.
Click here to listen to the audio file
Dr. Corrigan notes there are abundant examples of guideline adherence boosting quality outcomes, length of stay, and time to clinical stability.
Click here to listen to the audio file
Practical Neuroscience for Primary Care Physicians: Spring Issue
A supplement to Internal Medicine News.
Welcome Letter:
From the Publisher
Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.
Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.
Resources in the Spotlight
Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.
Practical Bits: Diagnostic Tools
A supplement to Internal Medicine News.
Welcome Letter:
From the Publisher
Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.
Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.
Resources in the Spotlight
Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.
Practical Bits: Diagnostic Tools
A supplement to Internal Medicine News.
Welcome Letter:
From the Publisher
Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.
Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.
Resources in the Spotlight
Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.
Practical Bits: Diagnostic Tools
ONLINE EXCLUSIVE: Audio interview with Roberta Fruth, PhD, RN, FAAN, JCR/JCI
Dr. Fruth suggests implementing standardized patient discharge education checklists, and says hospitalists "have been leading many workflow improvement projects."
Dr. Fruth suggests implementing standardized patient discharge education checklists, and says hospitalists "have been leading many workflow improvement projects."
Dr. Fruth suggests implementing standardized patient discharge education checklists, and says hospitalists "have been leading many workflow improvement projects."
ONLINE EXCLUSIVE: Evidence-Based Medicine Curveball
Even simple practice guidelines can be controversial. Guidelines are not created or implemented in a vacuum; they must be interpreted within a complex—and sometimes conflicting—milieu of medical, social, economic, and political forces.
This past November the U.S. Preventive Services Task Force, a federally funded, scientific advisory panel, released a 2009 update to its 2002 recommendations on breast cancer screening. The updated guideline said women in their 40s with an average risk for breast cancer do not need annual mammograms to screen for the disease, and older women at average risk of developing breast cancer need screening only once every two years.
The new guideline sparked disagreement among physicians, and a heated political debate as to whether the recommendation amounted to government-mandated, guideline-based, economically motivated healthcare rationing.
Some groups, including the American Cancer Society, said that mammograms have been proven to save lives by spotting tumors early on when they are most easily treated, and said they would stick by their current guideline to start annual mammogram screening at age 40. The Radiological Society of North America cited studies showing mammography of women in their 40s saves lives, and said about 20% of all breast cancer deaths in our country occur in women in their 40s.
The timing of the task force's recommendation was unfortunate (some lawmakers said it was calculated), as it was announced in the midst of the heated congressional healthcare reform debate. Although the new guideline would save a portion of the more than $5 billion spent on mammography in the U.S. each year, the task force said politics played no part in its recommendation, and that cost savings were never considered in its discussions. The task force acknowledged potential benefits of earlier testing, but attempted to balance those benefits with the potential harms of unnecessary radiation exposure, biopsies, overdiagnosis and overtreatment, and anxiety to women who get false positive results, which the panel said occurs in 10 percent of mammograms.
Even simple practice guidelines can be controversial. Guidelines are not created or implemented in a vacuum; they must be interpreted within a complex—and sometimes conflicting—milieu of medical, social, economic, and political forces.
This past November the U.S. Preventive Services Task Force, a federally funded, scientific advisory panel, released a 2009 update to its 2002 recommendations on breast cancer screening. The updated guideline said women in their 40s with an average risk for breast cancer do not need annual mammograms to screen for the disease, and older women at average risk of developing breast cancer need screening only once every two years.
The new guideline sparked disagreement among physicians, and a heated political debate as to whether the recommendation amounted to government-mandated, guideline-based, economically motivated healthcare rationing.
Some groups, including the American Cancer Society, said that mammograms have been proven to save lives by spotting tumors early on when they are most easily treated, and said they would stick by their current guideline to start annual mammogram screening at age 40. The Radiological Society of North America cited studies showing mammography of women in their 40s saves lives, and said about 20% of all breast cancer deaths in our country occur in women in their 40s.
The timing of the task force's recommendation was unfortunate (some lawmakers said it was calculated), as it was announced in the midst of the heated congressional healthcare reform debate. Although the new guideline would save a portion of the more than $5 billion spent on mammography in the U.S. each year, the task force said politics played no part in its recommendation, and that cost savings were never considered in its discussions. The task force acknowledged potential benefits of earlier testing, but attempted to balance those benefits with the potential harms of unnecessary radiation exposure, biopsies, overdiagnosis and overtreatment, and anxiety to women who get false positive results, which the panel said occurs in 10 percent of mammograms.
Even simple practice guidelines can be controversial. Guidelines are not created or implemented in a vacuum; they must be interpreted within a complex—and sometimes conflicting—milieu of medical, social, economic, and political forces.
This past November the U.S. Preventive Services Task Force, a federally funded, scientific advisory panel, released a 2009 update to its 2002 recommendations on breast cancer screening. The updated guideline said women in their 40s with an average risk for breast cancer do not need annual mammograms to screen for the disease, and older women at average risk of developing breast cancer need screening only once every two years.
The new guideline sparked disagreement among physicians, and a heated political debate as to whether the recommendation amounted to government-mandated, guideline-based, economically motivated healthcare rationing.
Some groups, including the American Cancer Society, said that mammograms have been proven to save lives by spotting tumors early on when they are most easily treated, and said they would stick by their current guideline to start annual mammogram screening at age 40. The Radiological Society of North America cited studies showing mammography of women in their 40s saves lives, and said about 20% of all breast cancer deaths in our country occur in women in their 40s.
The timing of the task force's recommendation was unfortunate (some lawmakers said it was calculated), as it was announced in the midst of the heated congressional healthcare reform debate. Although the new guideline would save a portion of the more than $5 billion spent on mammography in the U.S. each year, the task force said politics played no part in its recommendation, and that cost savings were never considered in its discussions. The task force acknowledged potential benefits of earlier testing, but attempted to balance those benefits with the potential harms of unnecessary radiation exposure, biopsies, overdiagnosis and overtreatment, and anxiety to women who get false positive results, which the panel said occurs in 10 percent of mammograms.
Flu Season, Part Deux
The public, physician, and media fascination with the H1N1 pandemic can serve as a healthy reminder this winter for hospitalists not to overlook seasonal influenza.
The attention focused on H1N1 influenza prompted the early release by the Journal of the American Medicine Association (JAMA. 2010;303[1]:doi10.1010/JAMA.2009.1911) of a study on the effectiveness of the virus’ vaccine. The attention also has prompted many hospitals to create processes for hospitalists and other staff to communicate with primary-care physicians (PCPs), community clinicians, and local health departments, according to Rick Hilger, MD, FHM, director of resident education of hospital medicine, and medical director of care management at Regions Hospital in Saint Paul, Minn. In particular, the attention on H1N1 has helped develop “open lines of communication” with infectious-disease doctors who often are the initial stop for influenza cases, Dr. Hilger says.
“When H1N1 was peaking this fall, we were getting probably biweekly e-mail updates as to what they were seeing in the community and them making recommendations,” says Dr. Hilger, who is also an assistant professor of medicine at the University of Minnesota. “I think we were spoiled in that respect. I would highly recommend that all hospitalists try to speak with … their local infectious-disease doctors to see what’s out there this winter.”
Dr. Hilger suggests hospitalists use the focus on influenza this winter to redouble efforts to vaccinate at-risk populations and work with infectious-disease specialists when patients are admitted with clinical signs of infection. He adds that hospitalists, as front-line staffers at small and community hospitals, should be used to dealing with seasonal influenza.
“I don’t think that seasonal influenza will be a sleeper problem, in general,” Dr. Hilger says. “We all have a lot of experience with it. If anything, H1N1 will increase our awareness of it because we can’t go a day without influenza activity being talked about, whether it’s within our hospitalist group or whether it’s in administration.”
The public, physician, and media fascination with the H1N1 pandemic can serve as a healthy reminder this winter for hospitalists not to overlook seasonal influenza.
The attention focused on H1N1 influenza prompted the early release by the Journal of the American Medicine Association (JAMA. 2010;303[1]:doi10.1010/JAMA.2009.1911) of a study on the effectiveness of the virus’ vaccine. The attention also has prompted many hospitals to create processes for hospitalists and other staff to communicate with primary-care physicians (PCPs), community clinicians, and local health departments, according to Rick Hilger, MD, FHM, director of resident education of hospital medicine, and medical director of care management at Regions Hospital in Saint Paul, Minn. In particular, the attention on H1N1 has helped develop “open lines of communication” with infectious-disease doctors who often are the initial stop for influenza cases, Dr. Hilger says.
“When H1N1 was peaking this fall, we were getting probably biweekly e-mail updates as to what they were seeing in the community and them making recommendations,” says Dr. Hilger, who is also an assistant professor of medicine at the University of Minnesota. “I think we were spoiled in that respect. I would highly recommend that all hospitalists try to speak with … their local infectious-disease doctors to see what’s out there this winter.”
Dr. Hilger suggests hospitalists use the focus on influenza this winter to redouble efforts to vaccinate at-risk populations and work with infectious-disease specialists when patients are admitted with clinical signs of infection. He adds that hospitalists, as front-line staffers at small and community hospitals, should be used to dealing with seasonal influenza.
“I don’t think that seasonal influenza will be a sleeper problem, in general,” Dr. Hilger says. “We all have a lot of experience with it. If anything, H1N1 will increase our awareness of it because we can’t go a day without influenza activity being talked about, whether it’s within our hospitalist group or whether it’s in administration.”
The public, physician, and media fascination with the H1N1 pandemic can serve as a healthy reminder this winter for hospitalists not to overlook seasonal influenza.
The attention focused on H1N1 influenza prompted the early release by the Journal of the American Medicine Association (JAMA. 2010;303[1]:doi10.1010/JAMA.2009.1911) of a study on the effectiveness of the virus’ vaccine. The attention also has prompted many hospitals to create processes for hospitalists and other staff to communicate with primary-care physicians (PCPs), community clinicians, and local health departments, according to Rick Hilger, MD, FHM, director of resident education of hospital medicine, and medical director of care management at Regions Hospital in Saint Paul, Minn. In particular, the attention on H1N1 has helped develop “open lines of communication” with infectious-disease doctors who often are the initial stop for influenza cases, Dr. Hilger says.
“When H1N1 was peaking this fall, we were getting probably biweekly e-mail updates as to what they were seeing in the community and them making recommendations,” says Dr. Hilger, who is also an assistant professor of medicine at the University of Minnesota. “I think we were spoiled in that respect. I would highly recommend that all hospitalists try to speak with … their local infectious-disease doctors to see what’s out there this winter.”
Dr. Hilger suggests hospitalists use the focus on influenza this winter to redouble efforts to vaccinate at-risk populations and work with infectious-disease specialists when patients are admitted with clinical signs of infection. He adds that hospitalists, as front-line staffers at small and community hospitals, should be used to dealing with seasonal influenza.
“I don’t think that seasonal influenza will be a sleeper problem, in general,” Dr. Hilger says. “We all have a lot of experience with it. If anything, H1N1 will increase our awareness of it because we can’t go a day without influenza activity being talked about, whether it’s within our hospitalist group or whether it’s in administration.”
Hospital Mortality Rates Improve, but Quality Gap Persists
Risk-adjusted mortality and complication rates have decreased nearly 11% from 2006 through 2008, according to the12th annual HealthGrades Quality in America Study. However, the report found a wide gap between the nation’s best hospitals and all others. To save thousands of lives, the authors suggested focused improvement in sepsis, pneumonia, heart failure, and respiratory failure.
The report showed patients at highly rated hospitals have a 52% lower chance of dying, compared with the U.S. hospital average, according to the study authors. The rankings used 40 million Medicare patient outcomes from 2006 to 2008, and analyzed more than 5,000 U.S. hospitals. The scoring was based on 30 common procedures and diagnoses.
Patrick Torcson, MD, FHM, chair of SHM’s Performance and Standards Committee, says hospitalists may be one reason highly rated hospitals did well. “We’re on-site to evaluate patients and facilitate transition of care,” Dr. Torcson says. “I think that’s where the biggest impact is going to be.”
At Christ Hospital in Cincinnati, one of the nation’s top performers, hospitalist Rajan Lakhia, DO, credits the “absolute attitude everyone around here has—a dedication to quality.”
Berc Gawne, MD, the hospital’s chief medical officer, agreed. “Hospitalists know the people, policies, and politics. They know the barriers and where to go to get things done,” he says. “It’s their hospital and they take ownership for the order sets, the critical pathways, and performance improvement.”
Scottsdale Healthcare in Arizona has improved its ratings in recent years. Perhaps not coincidentally, the facility hired a hospitalist group two years ago to improve the quality of care. According to hospitalist Barry Freeman, MD, each quarter, the hospital publishes quality measures, and goals are established as part of a scorecard. Results are regularly reviewed and improvement discussed. In taking care of almost all medical and surgical patients, the hospitalists “can further educate the nonhospitalist staff on quality efforts and initiatives under way,” Dr. Freeman explains.
Risk-adjusted mortality and complication rates have decreased nearly 11% from 2006 through 2008, according to the12th annual HealthGrades Quality in America Study. However, the report found a wide gap between the nation’s best hospitals and all others. To save thousands of lives, the authors suggested focused improvement in sepsis, pneumonia, heart failure, and respiratory failure.
The report showed patients at highly rated hospitals have a 52% lower chance of dying, compared with the U.S. hospital average, according to the study authors. The rankings used 40 million Medicare patient outcomes from 2006 to 2008, and analyzed more than 5,000 U.S. hospitals. The scoring was based on 30 common procedures and diagnoses.
Patrick Torcson, MD, FHM, chair of SHM’s Performance and Standards Committee, says hospitalists may be one reason highly rated hospitals did well. “We’re on-site to evaluate patients and facilitate transition of care,” Dr. Torcson says. “I think that’s where the biggest impact is going to be.”
At Christ Hospital in Cincinnati, one of the nation’s top performers, hospitalist Rajan Lakhia, DO, credits the “absolute attitude everyone around here has—a dedication to quality.”
Berc Gawne, MD, the hospital’s chief medical officer, agreed. “Hospitalists know the people, policies, and politics. They know the barriers and where to go to get things done,” he says. “It’s their hospital and they take ownership for the order sets, the critical pathways, and performance improvement.”
Scottsdale Healthcare in Arizona has improved its ratings in recent years. Perhaps not coincidentally, the facility hired a hospitalist group two years ago to improve the quality of care. According to hospitalist Barry Freeman, MD, each quarter, the hospital publishes quality measures, and goals are established as part of a scorecard. Results are regularly reviewed and improvement discussed. In taking care of almost all medical and surgical patients, the hospitalists “can further educate the nonhospitalist staff on quality efforts and initiatives under way,” Dr. Freeman explains.
Risk-adjusted mortality and complication rates have decreased nearly 11% from 2006 through 2008, according to the12th annual HealthGrades Quality in America Study. However, the report found a wide gap between the nation’s best hospitals and all others. To save thousands of lives, the authors suggested focused improvement in sepsis, pneumonia, heart failure, and respiratory failure.
The report showed patients at highly rated hospitals have a 52% lower chance of dying, compared with the U.S. hospital average, according to the study authors. The rankings used 40 million Medicare patient outcomes from 2006 to 2008, and analyzed more than 5,000 U.S. hospitals. The scoring was based on 30 common procedures and diagnoses.
Patrick Torcson, MD, FHM, chair of SHM’s Performance and Standards Committee, says hospitalists may be one reason highly rated hospitals did well. “We’re on-site to evaluate patients and facilitate transition of care,” Dr. Torcson says. “I think that’s where the biggest impact is going to be.”
At Christ Hospital in Cincinnati, one of the nation’s top performers, hospitalist Rajan Lakhia, DO, credits the “absolute attitude everyone around here has—a dedication to quality.”
Berc Gawne, MD, the hospital’s chief medical officer, agreed. “Hospitalists know the people, policies, and politics. They know the barriers and where to go to get things done,” he says. “It’s their hospital and they take ownership for the order sets, the critical pathways, and performance improvement.”
Scottsdale Healthcare in Arizona has improved its ratings in recent years. Perhaps not coincidentally, the facility hired a hospitalist group two years ago to improve the quality of care. According to hospitalist Barry Freeman, MD, each quarter, the hospital publishes quality measures, and goals are established as part of a scorecard. Results are regularly reviewed and improvement discussed. In taking care of almost all medical and surgical patients, the hospitalists “can further educate the nonhospitalist staff on quality efforts and initiatives under way,” Dr. Freeman explains.
Clinical Update: Challenges in the Management of Constipation and Other Gastrointestinal Disorders
A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.
To view the supplement, click the image above.
Topic Highlights
Gastrointestinal Disorders: When to Refer?
Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.
Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.
Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG
Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG
Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.
Recent H. pylori Literature Explores New Questions
A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.
To view the supplement, click the image above.
Topic Highlights
Gastrointestinal Disorders: When to Refer?
Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.
Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.
Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG
Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG
Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.
Recent H. pylori Literature Explores New Questions
A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.
To view the supplement, click the image above.
Topic Highlights
Gastrointestinal Disorders: When to Refer?
Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.
Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.
Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG
Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG
Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.
Recent H. pylori Literature Explores New Questions
Abuse Potential of Sleeping Agents: Liability Varies Among Agents
A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.
Topic Highlights
• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse
• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis
A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.
Topic Highlights
• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse
• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis
A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.
Topic Highlights
• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse
• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis
New Benchmarks in Acid-Related Disorders: A Debate With the Experts
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.
Improving Survival From Sudden Cardiac Arrest: Is it Time for Home Defibrillators?
A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.
To view the supplement, click the image above.
Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.
A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.
To view the supplement, click the image above.
Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.
A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.
To view the supplement, click the image above.
Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.
